Faisal Khurshid, an analyst from Leerink Partners, reiterated the Buy rating on PureTech Health. The associated price target is $46.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Faisal Khurshid has given his Buy rating due to a combination of factors, primarily focusing on the promising developments surrounding PureTech Health’s LYT-100. The initiation of Phase 3 trials for LYT-100, expected in the first half of 2026, is a significant milestone, especially given its potential as an improved treatment for idiopathic pulmonary fibrosis compared to the current standard of care. The creation of Celea Therapeutics, a new entity housing LYT-100, is seen as a strategic move that could enhance the company’s value over time.
Furthermore, the positive Phase 2b ELEVATE data supports the progression to Phase 3 trials, indicating a favorable efficacy and safety profile. The upcoming FDA meeting is anticipated to be a pivotal event, potentially facilitating regulatory alignment and trial design finalization. Khurshid also highlights the multiple sources of value within PureTech Health, including its wholly-owned programs and stakes in other founded entities, which collectively underpin the Buy rating.